- Report
- January 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- February 2024
- 250 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1214EUR$1,250USD£1,047GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1457EUR$1,500USD£1,257GBP
- Report
- March 2021
- 120 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- January 2022
- 70 Pages
Global
From €971EUR$1,000USD£838GBP
- Report
- May 2023
- 112 Pages
Global
From €3500EUR$3,860USD£3,125GBP
- Report
- January 2021
- 146 Pages
China, Global
From €3000EUR$3,309USD£2,679GBP
- Report
- April 2024
- 50 Pages
Global
From €2574EUR$2,650USD£2,220GBP
Somatropin is a type of endocrine and metabolic disorder drug used to treat growth hormone deficiency in children and adults. It is a synthetic form of human growth hormone, which is naturally produced in the body. Somatropin is used to treat growth failure due to inadequate secretion of growth hormone from the pituitary gland, as well as growth failure due to chronic kidney disease, Turner syndrome, Prader-Willi syndrome, and other causes. It is also used to treat short stature associated with Noonan syndrome, SHOX deficiency, and other causes.
Somatropin is available in both injectable and oral forms, and is typically administered as an injection under the skin. Common side effects of somatropin include headache, nausea, vomiting, and injection site reactions.
Some companies in the somatropin market include Pfizer, Novo Nordisk, Eli Lilly, Merck, and Sandoz. Show Less Read more